Download PDF
Open Access
CC BY-NC-ND 4.0 · Arq Neuropsiquiatr 2018; 76(02): 67-70
DOI: 10.1590/0004-282X20170188
Article

Does Parkinson's disease start in the gut?

A doença de Parkinson começa no intestino?

Authors

  • Oscar S. Gershanik

    1   Instituto de Neurociencias, Hospital Universitario Fundacion Favaloro, Laboratorio de Parkinson Experimental, ININFA-UBA-CONICET, Ciudad Autónoma de Buenos Aires, Argentina
Further Information
Also available at
  Permissions and Reprints

ABSTRACT

Current understanding of the pathophysiology of Parkinson's disease suggests a key role of the accumulation of alpha-synuclein in the pathogenesis. This critical review highlights major landmarks, hypotheses and controversies about the origin and progression of synucleinopathy in Parkinson's disease, leading to an updated review of evidence suggesting the enteric nervous system might be the starting point for the whole process. Although accumulating and compelling evidence favors this theory, the remaining knowledge gaps are important points for future studies.

RESUMO

O atual entendimento sobre a fisiopatologia da doença de Parkinson (DP) sugere um papel central do acúmulo de alfa-sinucleína na patogenia da DP Esta revisão crítica revisita marcos, teorias e controvérsias a respeito da origem e progressão da sinucleinopatia, apresentando uma atualização das principais evidências sugerindo que o sistema nervoso entérico seria o local inicial deste processo. Apesar das evidências a favor desta teoria serem crescentes e instigantes, as lacunas de conhecimento a este respeito são importantes pontos para estudos futuros.

Keywords:

Parkinson's disease - enteric nervous system - alpha-synuclein

Palavras-chave:

doença de Parkinson - sistema nervoso entérico - alfa-sinucleína


Publication History

Received: 25 September 2017

Accepted: 02 November 2017

Article published online:
28 August 2023

© 2023. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science. 1997 Jun;276(5321):2045-7. https://doi.org/10.1126/science.276.5321.2045
  • 2 Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997 Aug;388(6645):839-40. https://doi.org/10.1038/42166
  • 3 Klein C, Westenberger A. Genetics of Parkinson’s disease. Cold Spring Harb Perspect Med. 2012 Jan;2(1):a008888. https://doi.org/10.1101/cshperspect.a0088881
  • 4 Spillantini MG, Goedert M. The alpha-synucleinopathies: parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy. Ann N Y Acad Sci. 2000;920(1):16-27. https://doi.org/10.1111/j.1749-6632.2000.tb06900.x
  • 5 Konno T, Ross OA, Puschmann A, Dickson DW, Wszolek ZK. Autosomal dominant Parkinson’s disease caused by SNCA duplications. Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S1-6. https://doi.org/10.1016/j.parkreldis.2015.09.007
  • 6 Singleton AB, Farrer MJ, Bonifati V. The genetics of Parkinson’s disease: progress and therapeutic implications. Mov Disord. 2013 Jan;28(1):14-23. https://doi.org/10.1002/mds.25249
  • 7 Koprich JB, Kalia LV, Brotchie JM. Animal models of α-synucleinopathy for Parkinson disease drug development. Nat Rev Neurosci. 2017 Sep;18(9):515-29. https://doi.org/10.1038/nrn.2017.75
  • 8 Ingelsson M. Alpha-synuclein oligomers-neurotoxic molecules in Parkinson’s disease and other lewy body disorders. Front Neurosci. 2016 Sep;10:408. https://doi.org/10.3389/fnins.2016.00408
  • 9 Lim SY, Fox SH, Lang AE. Overview of the extranigral aspects of Parkinson disease. Arch Neurol. 2009 Feb;66(2):167-72. https://doi.org/10.1001/archneurol.2008.561
  • 10 Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rüb U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson’s disease (preclinical and clinical stages). J Neurol. 2002 Oct;249 Suppl 3:III/1-5. https://do.org/10.1007/s00415-002-1301-4
  • 11 Jellinger KA. A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. Biochim Biophys Acta. 2009 Jul;1792(7):730-40. https://doi.org/10.1016/j.bbadis.2008.07.006
  • 12 Rocha EM, Miranda B, Sanders LH. Alpha-synuclein: pathology, mitochondrial dysfunction and neuroinflammation in Parkinson’s disease. Neurobiol Dis. 2017 Apr 8. pii: S0969-9961(17)30080-3. https://doi.org/10.1016/j.nbd.2017.04.004
  • 13 Chu Y, Kordower JH. The prion hypothesis of Parkinson’s disease. Curr Neurol Neurosci Rep. 2015 May;15(5):28. https://doi.org/10.1007/s11910-015-0549-x
  • 14 Diógenes MJ, Dias RB, Rombo DM, Miranda HV, Maiolino F, Guerreiro P et al. Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation. J Neurosci. 2012 Aug;32(34):11750-62. https://doi.org/10.1523/JNEUROSCI.0234-12.2012
  • 15 Luk KC, Kehm VM, Zhang B, O’Brien P, Trojanowski JQ, Lee VM. Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J Exp Med. 2012 May;209(5):975-86. https://doi.org/10.1084/jem.20112457
  • 16 Luk KC, Kehm V, Carroll J, Zhang B, O’Brien P, Trojanowski JQ et al. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012 Nov;338(6109):949-53. https://doi.org/10.1126/science.1227157
  • 17 Shimozawa A, Ono M, Takahara D, Tarutani A, Imura S, Masuda-Suzukake M et al. Propagation of pathological α-synuclein in marmoset brain. Acta Neuropathol Commun. 2017 Feb;5(1):12. https://doi.org/10.1186/s40478-017-0413-0
  • 18 Recasens A, Dehay B, Bové J, Carballo-Carbajal I, Dovero S, Pérez-Villalba A et al. Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol. 2014 Mar;75(3):351-62. https://doi.org/10.1002/ana.24066
  • 19 Lindström V, Fagerqvist T, Nordström E, Eriksson F, Lord A, Tucker S et al. Immunotherapy targeting α-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] α-synuclein mice. Neurobiol Dis. 2014 Sep;69:134-43. https://doi.org/10.1016/j.nbd.2014.05.009
  • 20 Tran HT, Chung CH, Iba M, Zhang B, Trojanowski JQ, Luk KC et al. A-synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration. Cell Reports. 2014 Jun;7(6):2054-65. https://doi.org/10.1016/j.celrep.2014.05.033
  • 21 Houser MC, Tansey MG. The gut-brain axis: is intestinal inflammation a silent driver of Parkinson’s disease pathogenesis? NPJ Parkinsons Dis. 2017 Jan;3(1):3. https://doi.org/10.1038/s41531-016-0002-0
  • 22 Abbott RD, Petrovitch H, White LR, Masaki KH, Tanner CM, Curb JD et al. Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology. 2001 Aug;57(3):456-62. https://doi.org/10.1212/WNL.57.3.456
  • 23 Savica R, Carlin JM, Grossardt BR, Bower JH, Ahlskog JE, Maraganore DM et al. Medical records documentation of constipation preceding Parkinson disease: a case-control study. Neurology. 2009 Nov;73(21):1752-8. https://doi.org/10.1212/WNL.0b013e3181c34af5 PMID:19933976
  • 24 Ruffmann C, Parkkinen L. Gut feelings about α-Synuclein in gastrointestinal biopsies: biomarker in the making? Mov Disord. 2016 Feb;31(2):193-202. https://doi.org/10.1002/mds.26480
  • 25 Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res. 2004 Oct;318(1):121-34. https://doi.org/10.1007/s00441-004-0956-9
  • 26 Paillusson S, Clairembault T, Biraud M, Neunlist M, Derkinderen P. Activity-dependent secretion of alpha-synuclein by enteric neurons. J Neurochem. 2013 May;125(4):512-7. https://doi.org/10.1111/jnc.12131
  • 27 Forsyth CB, Shannon KM, Kordower JH, Voigt RM, Shaikh M, Jaglin JA et al. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson’s disease. PLoS One. 2011;6(12):e28032. https://doi.org/10.1371/journal.pone.0028032
  • 28 Pan-Montojo F, Schwarz M, Winkler C, Arnhold M, O’Sullivan GA, Pal A et al. Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice. Sci Rep. 2012;2(1):898. https://doi.org/10.1038/srep00898
  • 29 Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease. Cell. 2016 Dec;167(6):1469-1480.e12. https://doi.org/10.1016/j.cell.2016.11.018
  • 30 Ulusoy A, Musgrove RE, Rusconi R, Klinkenberg M, Helwig M, Schneider A et al. Neuron-to-neuron α-synuclein propagation in vivo is independent of neuronal injury. Acta Neuropathol Commun. 2015 Mar;3(1):13. https://doi.org/10.1186/s40478-015-0198-y
  • 31 Holmqvist S, Chutna O, Bousset L, Aldrin-Kirk P, Li W, Björklund T et al. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol. 2014 Dec;128(6):805-20. https://doi.org/10.1007/s00401-014-1343-6
  • 32 Svensson E, Horváth-Puhó E, Thomsen RW, Djurhuus JC, Pedersen L, Borghammer P et al. Vagotomy and subsequent risk of Parkinson’s disease. Ann Neurol. 2015 Oct;78(4):522-9. https://doi.org/10.1002/ana.24448
  • 33 Liu B, Fang F, Pedersen NL, Tillander A, Ludvigsson JF, Ekbom A et al. Vagotomy and Parkinson disease: aSwedish register-based matched-cohort study. Neurology. 2017 May;88(21):1996-2002. https://doi.org/10.1212/WNL.20170188201701883961